Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Last Friday, MindMed announced a $75M public offering priced at $7.00 a share. The timing, right before the FDA’s decision on Lykos’ MDMA NDA became known, was perhaps not entirely coincidental, with the psychedelic drug development field anticipating a period of volatile investor sentiment following the negative verdict. The raise comes on the back of a significant public offering…

Source